Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ITOS
- Price
- 5.65
- Stock movement up
- +0.47 (9.07%)
- Company name
- Iteos Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 206.42M
- Ent value
- 174.06M
- Price/Sales
- 8.71
- Price/Book
- 0.33
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -53.84%
- 3 year return
- -45.30%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ITOS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.71 |
| Price to Book | 0.33 |
| EV to Sales | 7.35 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 36.53M |
| EPS (TTM) | -2.81 |
| FCF per share (TTM) | -2.79 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 23.70M |
| Gross profit (TTM) | 22.85M |
| Operating income (TTM) | -150.34M |
| Net income (TTM) | -121.25M |
| EPS (TTM) | -2.81 |
| EPS (1y forward) | -3.81 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.43% |
| Operating margin (TTM) | -634.43% |
| Profit margin (TTM) | -511.68% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 123.74M |
| Net receivables | 42.80M |
| Total current assets | 544.88M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 723.08M |
| Accounts payable | 7.15M |
| Short/Current long term debt | 5.53M |
| Total current liabilities | 36.81M |
| Total liabilities | 91.39M |
| Shareholder's equity | 631.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -117.44M |
| Capital expenditures (TTM) | 2.88M |
| Free cash flow (TTM) | -120.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -19.20% |
| Return on Assets | -16.77% |
| Return on Invested Capital | -19.15% |
| Cash Return on Invested Capital | -19.01% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.21 |
| Daily high | 5.67 |
| Daily low | 5.11 |
| Daily Volume | 367K |
| All-time high | 47.86 |
| 1y analyst estimate | 27.00 |
| Beta | 1.39 |
| EPS (TTM) | -2.81 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 May 2025 |
Downside potential
Loading...
Downside potential data
| ITOS | S&P500 | |
| Current price drop from All-time high | -88.19% | -12.89% |
| Highest price drop | -89.47% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -53.68% | -11.07% |
| Avg time to new high | 40 days | 12 days |
| Max time to new high | 826 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
206.42M
Marketcap category
Small-cap
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Employees
157
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page